Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) President Michael Halstead sold 22,869 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Intra-Cellular Therapies Trading Down 0.7 %
Shares of NASDAQ:ITCI traded down $0.59 during midday trading on Thursday, hitting $87.63. 616,256 shares of the stock were exchanged, compared to its average volume of 865,137. The stock has a market cap of $9.29 billion, a P/E ratio of -102.34 and a beta of 0.97. Intra-Cellular Therapies, Inc. has a twelve month low of $54.17 and a twelve month high of $93.45. The company has a 50 day moving average price of $77.77 and a 200-day moving average price of $74.12.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $175.40 million for the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company’s quarterly revenue was up 39.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.25) EPS. On average, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.
Institutional Trading of Intra-Cellular Therapies
Analyst Ratings Changes
A number of research firms have recently commented on ITCI. The Goldman Sachs Group dropped their target price on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Needham & Company LLC restated a “buy” rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, October 30th. JPMorgan Chase & Co. raised their target price on Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Piper Sandler upgraded Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and raised their target price for the company from $68.00 to $92.00 in a research report on Friday, September 6th. Finally, Royal Bank of Canada lifted their price objective on Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, Intra-Cellular Therapies currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.23.
Get Our Latest Research Report on ITCI
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Read More
- Five stocks we like better than Intra-Cellular Therapies
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- What Are Some of the Best Large-Cap Stocks to Buy?
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- What Are Dividend Contenders? Investing in Dividend Contenders
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.